PetIQ, Inc. (PETQ) Reaches $23.50 After 9.00% Up Move; Profile of 5 Analysts Covering Bio-Techne (TECH)

January 14, 2018 - By Dolores Ford

Among 9 analysts covering BIO-TECHNE Corp (NASDAQ:TECH), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. BIO-TECHNE Corp had 18 analyst reports since August 18, 2015 according to SRatingsIntel. On Monday, October 23 the stock rating was maintained by Robert W. Baird with “Buy”. As per Thursday, November 10, the company rating was reinitiated by Leerink Swann. The stock of Bio-Techne Corporation (NASDAQ:TECH) earned “Neutral” rating by Janney Capital on Monday, March 27. The stock of Bio-Techne Corporation (NASDAQ:TECH) earned “Buy” rating by Deutsche Bank on Wednesday, August 9. On Tuesday, December 5 the stock rating was maintained by Leerink Swann with “Buy”. The rating was upgraded by Zacks on Tuesday, September 1 to “Sell”. On Tuesday, May 3 the stock rating was upgraded by Janney Capital to “Buy”. Citigroup initiated the stock with “Buy” rating in Thursday, February 9 report. The rating was initiated by Wells Fargo with “Hold” on Thursday, July 13. The firm has “Buy” rating by Robert W. Baird given on Tuesday, October 31. See Bio-Techne Corporation (NASDAQ:TECH) latest ratings:

05/12/2017 Broker: Leerink Swann Rating: Buy Maintain
31/10/2017 Broker: Robert W. Baird Rating: Buy New Target: $140.0 Maintain
23/10/2017 Broker: Robert W. Baird Rating: Buy New Target: $126.0 Maintain
24/10/2017 Broker: Citigroup Rating: Buy New Target: $145.0
30/08/2017 Broker: Deutsche Bank Rating: Buy New Target: $132.0
09/08/2017 Broker: Deutsche Bank Rating: Buy Old Target: $130 New Target: $132 Maintain

The stock of PetIQ, Inc. (NASDAQ:PETQ) is a huge mover today! The stock increased 4.17% or $0.94 during the last trading session, reaching $23.5. About 326,139 shares traded or 27.90% up from the average. PetIQ, Inc. (NASDAQ:PETQ) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 8 months positive chart setup for the $505.03 million company. It was reported on Jan, 14 by Barchart.com. We have $25.62 PT which if reached, will make NASDAQ:PETQ worth $45.45M more.

Analysts await PetIQ, Inc. (NASDAQ:PETQ) to report earnings on February, 5. PETQ’s profit will be $1.50M for 83.93 P/E if the $0.07 EPS becomes a reality. After $0.29 actual earnings per share reported by PetIQ, Inc. for the previous quarter, Wall Street now forecasts -75.86% negative EPS growth.

PetIQ, Inc. develops, manufactures, and sells pet medications, and health and wellness products for dogs and cats in the United States, Canada, and Europe. The company has market cap of $505.03 million. It offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements. It currently has negative earnings. The firm provides its products under the PetIQ, PetAction, Advecta, PetLock, Heart Shield, TruProfen, Betsy Farms, Minties, Vera, Delightibles, vetGuard, MimiÂ’s Market, PAWS IQ, VET + CHOICE, VET WORKS, TEX RANCH and VetIQ brands.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company has market cap of $5.25 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics. It has a 71.81 P/E ratio. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

Investors sentiment decreased to 1.21 in Q3 2017. Its down 0.23, from 1.44 in 2017Q2. It fall, as 16 investors sold Bio-Techne Corporation shares while 86 reduced holdings. 36 funds opened positions while 87 raised stakes. 35.91 million shares or 2.04% less from 36.66 million shares in 2017Q2 were reported. Summit Creek Llc accumulated 2.54% or 106,517 shares. Wasatch Advisors holds 7,169 shares or 0.01% of its portfolio. Geode Cap Mgmt Limited Liability Co owns 330,991 shares for 0.01% of their portfolio. Peak6 Invests Limited Partnership reported 1,840 shares stake. Moreover, Envestnet Asset has 0% invested in Bio-Techne Corporation (NASDAQ:TECH) for 9,665 shares. First Light Asset Management Lc holds 1.48% or 38,654 shares. Bridgewater Assoc L P holds 0% in Bio-Techne Corporation (NASDAQ:TECH) or 1,955 shares. First Trust Advsr Lp stated it has 0.11% in Bio-Techne Corporation (NASDAQ:TECH). Fifth Third Commercial Bank owns 526 shares. Dekabank Deutsche Girozentrale stated it has 0.02% of its portfolio in Bio-Techne Corporation (NASDAQ:TECH). Underhill Invest Mgmt Llc reported 0.12% of its portfolio in Bio-Techne Corporation (NASDAQ:TECH). 337 were reported by Greenleaf Tru. Castleark Mgmt Limited Liability Corporation stated it has 43,240 shares. Ww Asset Mngmt invested in 2,724 shares or 0.01% of the stock. Lord Abbett & Com Limited Liability Company reported 326,863 shares.

The stock increased 1.34% or $1.85 during the last trading session, reaching $140.02. About 139,484 shares traded. Bio-Techne Corporation (NASDAQ:TECH) has risen 6.75% since January 14, 2017 and is uptrending. It has underperformed by 9.95% the S&P500.

Since August 10, 2017, it had 0 insider buys, and 4 insider sales for $164,629 activity. $128,909 worth of Bio-Techne Corporation (NASDAQ:TECH) was sold by HOLBROOK KAREN A. 100 Bio-Techne Corporation (NASDAQ:TECH) shares with value of $11,430 were sold by LUCAS ROGER C.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>